REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the publication of long ...
WASHINGTON & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx®, Inc. today announced the results of two multi-center, randomized clinical trials showing clinically meaningful improvements in lung ...
VIENNA — Bronchoscopic lung volume reduction (BLVR) was associated with sustained improvements in adults with severe emphysema over a 5-year period, based on data from 190 individuals. The LIBERATE ...
Positive Coverage Policy from Health Care Service Corporation (HCSC) Covers Blue Cross Blue Shield Members in Illinois, Montana, New Mexico, Oklahoma and Texas REDWOOD CITY, Calif., Nov. 02, 2020 ...
Daily, people all around West Michigan and the world feel like they are suffocating. It's not because of the stress daily life can bring, but because of a condition known as COPD with Emphysema. The ...
Over 20,000 Patients Treated with the Non-Surgical Zephyr Valve for Severe Emphysema, a Form of COPD
REDWOOD CITY, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- As part of COPD Awareness Month, Pulmonx Corporation is announcing that over 20,000 patients have been treated worldwide with their Zephyr® ...
Temple University Hospital has become the first U.S. center to perform bronchoscopic lung volume reduction using implantation of the Zephyr® Endobronchial Valve (Zephyr® EBV®) to treat severe ...
Pulmonx ® Corp. announced today that the U.S. Food and Drug Administration (FDA) has approved the Zephyr ® Endobronchial Valve System for treating severe emphysema patients. The Zephyr Valve is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback